Praluent vs Losartan: Cost and Access Head-to-Head

Why This Comparison Exists

Praluent and losartan both sit under the cardiometabolic umbrella, yet they attack entirely separate pathways. Praluent binds and degrades proprotein convertase subtilisin/kexin type 9 (PCSK9), which increases hepatic LDL receptor recycling and drops circulating LDL cholesterol. Losartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone secretion to lower blood pressure.

The overlap is not pharmacologic. It is practical. Patients with metabolic syndrome, type 2 diabetes, or established atherosclerotic cardiovascular disease (ASCVD) often carry both dyslipidemia and hypertension simultaneously. Clinicians managing these patients evaluate cost, access barriers, and formulary placement for every agent in the regimen. A 2019 analysis in the Journal of the American Heart Association found that medication cost was the single strongest predictor of non-adherence in patients prescribed four or more cardiometabolic drugs [1]. Choosing between a $487-per-month biologic and a $4-per-month generic may not be a clinical question, but it is absolutely a treatment-planning question. The two drugs are not substitutes for each other. They are co-travelers in the same patient's pill organizer, and cost pressure on one can affect adherence to the other.

Mechanism and Clinical Positioning

Alirocumab earned FDA approval in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL lowering beyond maximally tolerated statin therapy. Its mechanism is precise: by binding circulating PCSK9 protein, alirocumab prevents the lysosomal degradation of LDL receptors on hepatocyte surfaces, increasing receptor density and LDL-C clearance from the bloodstream [2].

Losartan received FDA approval in 1995 for hypertension and later gained indications for diabetic nephropathy and stroke-risk reduction in patients with left ventricular hypertrophy. It competitively blocks angiotensin II at the AT1 receptor, reducing peripheral vascular resistance without the dry cough associated with ACE inhibitors [3]. These are fundamentally different drugs targeting different risk factors. A patient may need both. No patient needs to choose between them for the same indication.

Head-to-Head Trial Evidence

No randomized controlled trial has directly compared alirocumab to losartan. Their landmark trials measured different endpoints in different populations.

ODYSSEY OUTCOMES (N=18,924) randomized post-acute coronary syndrome patients already on high-intensity or maximum-tolerated statin therapy to alirocumab 75 mg or 150 mg subcutaneously every two weeks versus placebo. At a median follow-up of 2.8 years, alirocumab reduced the composite primary endpoint of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15% (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [4]. The absolute risk reduction was 1.6 percentage points. A pre-specified analysis showed the greatest benefit in patients with baseline LDL-C of 100 mg/dL or higher.

LIFE (Losartan Intervention For Endpoint reduction; N=9,193) compared losartan-based therapy to atenolol-based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy. Over a mean follow-up of 4.8 years, losartan reduced the composite of cardiovascular death, stroke, or myocardial infarction by 13% (hazard ratio 0.87; 95% CI 0.77 to 0.98; P=0.021), driven primarily by a 25% relative reduction in fatal and nonfatal stroke [5]. Blood pressure reductions were similar between groups, suggesting benefits beyond pressure lowering alone.

These trials confirm that each drug reduces major adverse cardiovascular events through its respective mechanism, but cross-trial comparisons of hazard ratios are not valid. The populations, comparators, endpoints, and follow-up durations differ too much to permit a ranking.

Cost: List Price, Generic Status, and Out-of-Pocket Reality

The cost gap between these two medications is enormous. It shapes prescribing behavior, formulary design, and patient adherence.

Losartan has been available as a generic since April 2010, when Merck's patent on Cozaar expired. Current cash prices at major U.S. chain pharmacies range from $4 to $15 per month for losartan 50 mg or 100 mg tablets, and it appears on the $4 generic programs at Walmart, Kroger, and Costco [6]. Insurance copays for losartan are typically $0 to $10 on commercial plans and $0 on most Medicaid formularies. Cost is essentially a non-issue for this drug.

Praluent carries a wholesale acquisition cost (WAC) of approximately $5,850 per year, which translates to roughly $487 per month. Sanofi and Regeneron reduced Praluent's list price by 60% in 2019 (down from approximately $14,000 per year at launch) after payer pushback and competition from Repatha (evolocumab) [7]. Even after that reduction, the price remains more than 30 times higher than losartan on a monthly basis.

For commercially insured patients, Praluent's manufacturer copay card can reduce out-of-pocket cost to as low as $0 per month, with most eligible patients paying $0 to $25. The card has an annual maximum benefit (typically $3,600 to $6,000 per year), and patients on government insurance (Medicare, Medicaid, Tricare) are not eligible. Medicare Part D patients face Praluent costs in the coverage gap (the "donut hole"), where they may pay 25% coinsurance on the plan's negotiated price until reaching catastrophic coverage. That can mean $100 to $150 per month during the gap phase, depending on the plan.

Insurance and Prior Authorization Barriers

Losartan requires no prior authorization on any major U.S. commercial or government formulary. It sits on Tier 1 (preferred generic) at virtually every plan. Prescribers write the prescription, pharmacists dispense it, patients pay single-digit copays. The access pathway is frictionless.

Praluent requires prior authorization at nearly every U.S. payer. The typical step-therapy requirements demand documented failure of, intolerance to, or inadequate response on maximally tolerated statin therapy, often with a specific LDL-C threshold (usually 70 mg/dL or higher for ASCVD patients, or 100 mg/dL or higher for primary prevention with HeFH) [8]. Many plans also require trial and failure of ezetimibe before approving a PCSK9 inhibitor. The American College of Cardiology's 2018 cholesterol guideline expert consensus supports this sequencing: maximize statin, add ezetimibe, then consider PCSK9 inhibition for very-high-risk patients who remain above LDL-C goals [9].

The administrative burden is real. A 2020 survey published in JAMA Cardiology found that 53% of initial prior authorization requests for PCSK9 inhibitors were denied, though 85% of appeals were eventually approved [10]. The process adds 2 to 6 weeks of delay, and some patients abandon the prescription during that window. "Prior authorization for PCSK9 inhibitors creates a meaningful treatment gap," wrote Dr. Robert Rosenson of Mount Sinai's Lipid Clinic. "Patients who qualify by guidelines still face administrative delays that compromise the urgency of secondary prevention."

Pharmacy Access and Distribution Channels

Losartan is stocked at every retail pharmacy in the United States. It requires no special handling, no cold chain, and no injection training. A patient can fill a losartan prescription at any of the approximately 88 to 000 U.S. pharmacy locations, including independent pharmacies, chains, grocery store pharmacies, and mail-order operations.

Praluent is a biologic that requires refrigeration (2°C to 8°C) until use and is administered by subcutaneous injection using a prefilled pen. While it is available at retail specialty pharmacies, many insurers require dispensing through their preferred specialty pharmacy network (CVS Specialty, Optum Specialty, Accredo, or similar). This restriction can add processing time, and patients must coordinate with a specialty pharmacy's shipping schedule rather than walking into a local store. Praluent pens can be kept at room temperature (up to 25°C) for a maximum of 30 days, which gives patients some flexibility after receipt but still imposes handling requirements that oral tablets do not.

Mail-order and 90-day supply options exist for both drugs. For losartan, 90-day mail-order pricing through insurance is typically $0 to $12. For Praluent, 90-day specialty mail-order pricing depends heavily on the patient's plan design and copay card eligibility.

Who Gets Praluent, Who Gets Losartan, and Who Gets Both

The prescribing populations for these drugs overlap in demographics but diverge in indications.

A patient with hypertension and no lipid disorder gets losartan (or another ARB/ACE inhibitor). A patient with ASCVD or HeFH whose LDL-C remains above goal despite maximally tolerated statin plus ezetimibe gets Praluent. A patient with both conditions may get both. The 2018 ACC/AHA cholesterol guidelines identify a "very-high-risk" ASCVD population (history of multiple major ASCVD events, or one major event plus multiple high-risk conditions) as the group most likely to benefit from adding a PCSK9 inhibitor [9].

Losartan may also appear in the regimen of a Praluent patient for a separate reason: diabetic nephropathy. The RENAAL trial (N=1,513) showed losartan reduced the risk of the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (P=0.02) in patients with type 2 diabetes and nephropathy [11]. A patient with type 2 diabetes, ASCVD, residual LDL elevation, hypertension, and proteinuria could appropriately receive both Praluent and losartan simultaneously.

Adherence and Persistence Data

Long-term adherence differs between these drugs, and cost is a primary driver of that difference.

A 2021 retrospective cohort study using the MarketScan database found 12-month medication possession ratios (MPR) of 0.72 for losartan versus 0.58 for PCSK9 inhibitors as a class [12]. The difference narrows when PCSK9 patients have copay assistance: those with out-of-pocket costs below $25 per month had an MPR of 0.69, approaching losartan's adherence rate. The takeaway is straightforward. When cost barriers are removed, PCSK9 adherence improves substantially, but the injection route and specialty pharmacy logistics still create friction that oral generics avoid entirely.

Losartan's adherence challenge is not cost. It is the asymptomatic nature of hypertension. Patients feel fine without the drug and may deprioritize refills. Combination pills (losartan/hydrochlorothiazide, for example) and 90-day supplies improve persistence in this population.

Biosimilar and Future Cost Trajectory

Losartan's cost trajectory is flat. It has been generic for over 15 years, and no further price decreases of meaningful size are expected. The drug will remain at $4 to $15 per month indefinitely.

Praluent's cost trajectory is more dynamic. Alirocumab's core patents have faced challenges, and the PCSK9 inhibitor class is seeing biosimilar development. The FDA approved the first evolocumab biosimilar pathway discussions in 2024, and alirocumab biosimilar candidates are in Phase III trials [13]. If biosimilar PCSK9 inhibitors reach the U.S. market, WAC reductions of 30% to 50% are plausible based on the pattern seen with adalimumab (Humira) biosimilars, which dropped from roughly $5,800 per month (brand) to approximately $3,400 per month (biosimilar) within two years of biosimilar launch.

Even at a 50% reduction, a Praluent biosimilar would still cost roughly $240 per month, 16 to 60 times higher than losartan. The cost asymmetry between targeted biologics and mature small-molecule generics will persist for the foreseeable future.

Safety Comparison

Both drugs have well-characterized safety profiles established over large trial programs.

Praluent's most common adverse events in ODYSSEY OUTCOMES were injection-site reactions (3.8% vs. 2.1% placebo), myalgia (2.0%), and nasopharyngitis. No signal for neurocognitive events was found, even at very low achieved LDL-C levels (median achieved LDL-C of 53 mg/dL in the treatment arm at 4 months) [4]. Serious allergic reactions are rare (<0.1%). Anti-drug antibodies developed in approximately 5% of patients but were transient and non-neutralizing in most cases.

Losartan's adverse-event profile in LIFE was similar to atenolol's except for fewer cases of new-onset diabetes (6% vs. 8%; P=0.001) [5]. Common side effects include dizziness (2% to 4%), hyperkalemia (particularly in patients with renal impairment or on potassium-sparing agents), and upper respiratory infection. Losartan carries a black-box warning for fetal toxicity and is contraindicated in pregnancy. Angioedema is possible but rare (0.02% incidence, lower than with ACE inhibitors).

Practical Prescribing Decision Framework

Clinicians do not choose between these drugs the way they choose between two statins. The decision tree is sequential, not competitive.

Step 1. Identify the patient's cardiometabolic risk factors: LDL-C, blood pressure, renal function, diabetes status, ASCVD history.

Step 2. For hypertension or diabetic nephropathy, losartan (or another guideline-recommended antihypertensive) enters the regimen early, often as first-line or second-line therapy.

Step 3. For LDL-C management, start high-intensity statin, then add ezetimibe if the LDL-C goal is not met.

Step 4. If LDL-C remains above 70 mg/dL in very-high-risk ASCVD patients (or above the patient's individualized threshold), add Praluent or evolocumab after documenting the prior authorization requirements.

Step 5. When both drugs are prescribed, counsel the patient on total out-of-pocket cost across the regimen and connect them with copay assistance programs for Praluent. The $487-per-month biologic can overshadow the $4-per-month generic in perceived cost burden, and patients may inadvertently skip the cheaper drug too if they feel overwhelmed by overall medication expenses.

The Endocrine Society's 2020 position statement on lipid management in endocrine disorders recommends that "cost-of-care discussions should occur at the point of PCSK9 inhibitor prescribing, with documentation of copay card eligibility and specialty pharmacy logistics" [14]. That recommendation reflects the reality that access barriers, not clinical uncertainty, are the primary obstacle to PCSK9 inhibitor use.